🍽️ dexfenfluramine hydrochloride,(prescription)

AI Engines For more Details: Perplexity Kagi Labs You

Appetite Suppression: Dexfenfluramine hydrochloride is a serotoninergic agent that was used to suppress appetite and promote weight loss in individuals with obesity. It acted by increasing serotonin levels in the brain, which in turn reduced appetite and food intake.
Withdrawal from Market: Dexfenfluramine hydrochloride, along with its closely related medication fenfluramine, was withdrawn from the market in the late 1990s due to safety concerns regarding serious cardiovascular side effects. These side effects included cardiac valve abnormalities and primary pulmonary hypertension (PPH), a rare but potentially life-threatening condition characterized by high blood pressure in the arteries of the lungs.
Cardiovascular Risks: The use of dexfenfluramine hydrochloride and fenfluramine was associated with an increased risk of valvular heart disease, particularly involving the mitral and aortic valves. The medications were also linked to an elevated risk of PPH, a condition that can lead to severe respiratory and cardiovascular complications.
FDA Action: In 1997, the U.S. Food and Drug Administration (FDA) requested the voluntary withdrawal of dexfenfluramine hydrochloride (Redux) and fenfluramine (Pondimin) from the market following reports of cardiac valve abnormalities and PPH in individuals taking these medications for weight loss. The FDA concluded that the risks associated with these drugs outweighed their potential benefits for weight loss.
Regulatory Actions: In addition to the FDA's withdrawal of dexfenfluramine hydrochloride and fenfluramine from the market, regulatory agencies in other countries also took similar actions to restrict or suspend the use of these medications due to safety concerns. Dexfenfluramine hydrochloride is no longer available for prescription or commercial use in most countries worldwide.
Long-Term Health Impacts: Individuals who were previously prescribed dexfenfluramine hydrochloride or fenfluramine for weight loss should be aware of the potential long-term health impacts associated with these medications, particularly cardiovascular complications such as valvular heart disease and PPH. Regular monitoring and follow-up with a healthcare provider may be necessary to assess and manage any potential adverse effects.

;

Check for interactions on Supp.AI | 📚 PubMed Citations

Data Contradictions — Limits of Certainity

Impacted of dexfenfluramine hydrochloride,(prescription) On Probiotics

Rank	Probiotic	Impact
species	Bacteroides uniformis	Reduces
species	Escherichia coli	Reduces

Bacteria Impacted by dexfenfluramine hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?
📓 Direct Citations	👪👶 Indirect Citations	Taxonomy	Rank	Effect
0	1	Fusobacterium	genus	Decreases
0	1	Bilophila	genus	Decreases
0	1	Lacrimispora	genus	Decreases
0	1	Mediterraneibacter	genus	Decreases
0	1	Streptococcus	genus	Decreases
0	1	Roseburia	genus	Decreases
0	1	Escherichia	genus	Decreases
0	1	Thomasclavelia	genus	Decreases
0	1	Bacteroides	genus	Decreases
0	1	Parabacteroides	genus	Decreases
0	1	Segatella	genus	Decreases
0	1	Escherichia coli O1:K1:H7	no rank	Decreases
0	1	Escherichia coli O139:H1	no rank	Decreases
0	1	Escherichia coli O141:H4	no rank	Decreases
0	1	Escherichia coli O145:H34	no rank	Decreases
0	1	Escherichia coli O15:H12	no rank	Decreases
0	1	Escherichia coli O155:H21	no rank	Decreases
0	1	Escherichia coli O158:H23	no rank	Decreases
0	1	Escherichia coli O16:H48	no rank	Decreases
0	1	Escherichia coli O170:H18	no rank	Decreases
0	1	Escherichia coli O18ac:H14	no rank	Decreases
0	1	Escherichia coli O19:H7	no rank	Decreases
0	1	Escherichia coli O2:K1:H4	no rank	Decreases
0	1	Escherichia coli O2:K1:H5	no rank	Decreases
0	1	Escherichia coli O2:K1:H7	no rank	Decreases
0	1	Escherichia coli O20:H12	no rank	Decreases
0	1	Escherichia coli O25:H16	no rank	Decreases
0	1	Escherichia coli O55:H7	no rank	Decreases
0	1	Escherichia coli O68:H12	no rank	Decreases
0	1	Escherichia coli O7:H15	no rank	Decreases
0	1	Escherichia coli O78:H51	no rank	Decreases
0	1	Escherichia coli O80:H26	no rank	Decreases
0	1	Escherichia coli O84:H7	no rank	Decreases
0	1	Escherichia coli O85:H1	no rank	Decreases
0	1	Escherichia coli O103	serogroup	Decreases
0	1	Escherichia coli O111	serogroup	Decreases
0	1	Escherichia coli O119	serogroup	Decreases
0	1	Escherichia coli O121	serogroup	Decreases
0	1	Escherichia coli O145	serogroup	Decreases
0	1	Escherichia coli O155	serogroup	Decreases
0	1	Escherichia coli O157	serogroup	Decreases
0	1	Escherichia coli O177	serogroup	Decreases
0	1	Escherichia coli O26	serogroup	Decreases
0	1	Escherichia coli O3	serogroup	Decreases
0	1	Escherichia coli O43	serogroup	Decreases
0	1	Escherichia coli O5	serogroup	Decreases
0	1	Escherichia coli O78	serogroup	Decreases
0	1	Escherichia coli O86	serogroup	Decreases
0	1	Escherichia coli O91	serogroup	Decreases
0	1	Escherichia coli H20	serotype	Decreases
0	1	Escherichia coli O1:H42	serotype	Decreases
0	1	Escherichia coli O1:HNT	serotype	Decreases
0	1	Escherichia coli O10:H32	serotype	Decreases
0	1	Escherichia coli O10:K5(L):H4	serotype	Decreases
0	1	Escherichia coli O100:H21	serotype	Decreases
0	1	Escherichia coli O103:H11	serotype	Decreases
0	1	Escherichia coli O103:H2	serotype	Decreases
0	1	Escherichia coli O103:H25	serotype	Decreases
0	1	Escherichia coli O104:H21	serotype	Decreases
0	1	Escherichia coli O104:H4	serotype	Decreases
0	1	Escherichia coli O111:H-	serotype	Decreases
0	1	Escherichia coli O111:H11	serotype	Decreases
0	1	Escherichia coli O111:H8	serotype	Decreases
0	1	Escherichia coli O111:NM	serotype	Decreases
0	1	Escherichia coli O112ab:H8	serotype	Decreases
0	1	Escherichia coli O112ac:H19	serotype	Decreases
0	1	Escherichia coli O113:H21	serotype	Decreases
0	1	Escherichia coli O114:H49	serotype	Decreases
0	1	Escherichia coli O118:H16	serotype	Decreases
0	1	Escherichia coli O121:H19	serotype	Decreases
0	1	Escherichia coli O121:H7	serotype	Decreases
0	1	Escherichia coli O123:H11	serotype	Decreases
0	1	Escherichia coli O125ac:K+:H10	serotype	Decreases
0	1	Escherichia coli O126:H45	serotype	Decreases
0	1	Escherichia coli O127:H27	serotype	Decreases
0	1	Escherichia coli O127:H6	serotype	Decreases
0	1	Escherichia coli O128:H2	serotype	Decreases
0	1	Escherichia coli O128ac:H12	serotype	Decreases
0	1	Escherichia coli O139:H28	serotype	Decreases
0	1	Escherichia coli O145:H25	serotype	Decreases
0	1	Escherichia coli O145:H28	serotype	Decreases
0	1	Escherichia coli O145:NM	serotype	Decreases
0	1	Escherichia coli O146:H21	serotype	Decreases
0	1	Escherichia coli O15:H18	serotype	Decreases
0	1	Escherichia coli O150:H6	serotype	Decreases
0	1	Escherichia coli O152:H23	serotype	Decreases
0	1	Escherichia coli O153:H2	serotype	Decreases
0	1	Escherichia coli O156:H25	serotype	Decreases
0	1	Escherichia coli O157:H-	serotype	Decreases
0	1	Escherichia coli O157:H43	serotype	Decreases
0	1	Escherichia coli O157:H7	serotype	Decreases
0	1	Escherichia coli O157:NM	serotype	Decreases
0	1	Escherichia coli O16:H6	serotype	Decreases
0	1	Escherichia coli O165:H25	serotype	Decreases
0	1	Escherichia coli O167:H26	serotype	Decreases
0	1	Escherichia coli O174:H2	serotype	Decreases
0	1	Escherichia coli O174:H21	serotype	Decreases
0	1	Escherichia coli O174:H8	serotype	Decreases
0	1	Escherichia coli O176:H45	serotype	Decreases
0	1	Escherichia coli O177:NM	serotype	Decreases
0	1	Escherichia coli O2:H6	serotype	Decreases
0	1	Escherichia coli O2:K2:H1	serotype	Decreases
0	1	Escherichia coli O25:H1	serotype	Decreases
0	1	Escherichia coli O25:NM	serotype	Decreases
0	1	Escherichia coli O26:H1	serotype	Decreases
0	1	Escherichia coli O26:H11	serotype	Decreases
0	1	Escherichia coli O28ac:NM	serotype	Decreases
0	1	Escherichia coli O29:H4	serotype	Decreases
0	1	Escherichia coli O32:H37	serotype	Decreases
0	1	Escherichia coli O39:NM	serotype	Decreases
0	1	Escherichia coli O44:H18	serotype	Decreases
0	1	Escherichia coli O45:H2	serotype	Decreases
0	1	Escherichia coli O6:H16	serotype	Decreases
0	1	Escherichia coli O6:H16:CFA/II	serotype	Decreases
0	1	Escherichia coli O6:K2:H1	serotype	Decreases
0	1	Escherichia coli O69:H11	serotype	Decreases
0	1	Escherichia coli O7:H4	serotype	Decreases
0	1	Escherichia coli O7:K1	serotype	Decreases
0	1	Escherichia coli O78:H12	serotype	Decreases
0	1	Escherichia coli O78:H4	serotype	Decreases
0	1	Escherichia coli O79:H7	serotype	Decreases
0	1	Escherichia coli O8:H8	serotype	Decreases
0	1	Escherichia coli O81:NM	serotype	Decreases
0	1	Escherichia coli O83:H1	serotype	Decreases
0	1	Escherichia coli O86:H34	serotype	Decreases
0	1	Escherichia coli O89m:H10	serotype	Decreases
0	1	Escherichia coli O89m:H9	serotype	Decreases
0	1	Escherichia coli O9:H10	serotype	Decreases
0	1	Escherichia coli O91:H14	serotype	Decreases
0	1	Escherichia coli O91:NM	serotype	Decreases
0	1	Escherichia coli O99:H6	serotype	Decreases
0	1	Escherichia coli ONT:H33	serotype	Decreases
1	0	Bilophila wadsworthia	species	Decreases
1	0	Lacrimispora saccharolytica	species	Decreases
1	0	Fusobacterium nucleatum	species	Decreases
1	0	Mediterraneibacter gnavus	species	Decreases
1	0	Streptococcus salivarius	species	Decreases
1	0	Roseburia intestinalis	species	Decreases
1	0	Escherichia coli	species	Decreases
1	0	Bacteroides fragilis	species	Decreases
1	0	Thomasclavelia ramosa	species	Decreases
1	0	Bacteroides uniformis	species	Decreases
1	0	Parabacteroides merdae	species	Decreases
1	0	Segatella copri	species	Decreases
0	1	Fusobacterium nucleatum subsp. nucleatum	subspecies	Decreases

Impact of dexfenfluramine hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition	Positive Impact	Negative Impact	Benefit Ratio Impact
Abdominal Aortic Aneurysm	0.3		0.3
ADHD	0.7		0.7
Age-Related Macular Degeneration and Glaucoma	0.1	0	0
Allergic Rhinitis (Hay Fever)	0.8	0.4	1
Allergies	1	0.5	1
Allergy to milk products	0.3	0.2	0.5
Alzheimer's disease	1.8	1.6	0.13
Amyotrophic lateral sclerosis (ALS) Motor Neuron	0.4	0.3	0.33
Ankylosing spondylitis	0.6	0.9	-0.5
Anorexia Nervosa	0.1	0.6	-5
Antiphospholipid syndrome (APS)	0.7	0.3	1.33
Asthma	1.5	0.4	2.75
Atherosclerosis	1	0.4	1.5
Atrial fibrillation	0.5	0.6	-0.2
Autism	1.6	1.7	-0.06
Autoimmune Disease	0.3	0.1	2
Barrett esophagus cancer	0.4	0.1	3
benign prostatic hyperplasia	0.1	0.1	0
Biofilm	1.5		1.5
Bipolar Disorder	0.5	0.1	4
Brain Trauma	0.1	0.2	-1
Breast Cancer	0.9		0.9
Cancer (General)	0.4		0.4
Carcinoma	1.6	0.1	15
Celiac Disease	1	0.4	1.5
Cerebral Palsy	0.2	0.2	0
Chronic Fatigue Syndrome	1.4	0.9	0.56
Chronic Kidney Disease	0.7	0.4	0.75
Chronic Lyme		0.2	-0.2
Chronic Obstructive Pulmonary Disease (COPD)	1	0.6	0.67
Chronic Urticaria (Hives)	0.5	0.3	0.67
Coagulation / Micro clot triggering bacteria	0.5	0.3	0.67
Cognitive Function	0.2	0.3	-0.5
Colorectal Cancer	2.5	0.5	4
Constipation	0.2	0.1	1
Coronary artery disease	1	0.5	1
COVID-19	1.3	1.7	-0.31
Crohn's Disease	2.8	0.8	2.5
Cushing's Syndrome (hypercortisolism)		0.1	-0.1
cystic fibrosis	0.4	0.2	1
d-lactic acidosis (one form of brain fog)	0.3		0.3
deep vein thrombosis	1.2	0.4	2
Denture Wearers Oral Shifts	1		1
Depression	1.9	0.8	1.37
Dermatomyositis	0.1		0.1
Eczema	1.1	0.7	0.57
Endometriosis	0.6	0.4	0.5
Eosinophilic Esophagitis	0.4	0.1	3
Epilepsy	1.2	0.1	11
erectile dysfunction	0.6		0.6
Fibromyalgia	0.4	0.2	1
Functional constipation / chronic idiopathic constipation	1.1	0.5	1.2
gallstone disease (gsd)	1.1	0.5	1.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus	1.2	0.1	11
Generalized anxiety disorder	1.4	0.2	6
Glioblastoma		0.1	-0.1
Gout	0.2		0.2
Graves' disease	0.1	0.4	-3
Gulf War Syndrome	0.1	0.3	-2
Halitosis	1.2	0.1	11
Hashimoto's thyroiditis	0.8	0.4	1
Heart Failure	1.7	0.1	16
hemorrhagic stroke	0.4		0.4
Hidradenitis Suppurativa	0.9		0.9
High Histamine/low DAO	0.4		0.4
hypercholesterolemia (High Cholesterol)	0.3		0.3
hyperglycemia	0.7	0.1	6
Hyperlipidemia (High Blood Fats)	0.3		0.3
hypersomnia		0.3	-0.3
hypertension (High Blood Pressure	0.4	0.9	-1.25
Hypoxia	0.5		0.5
IgA nephropathy (IgAN)	0.6	0.7	-0.17
Inflammatory Bowel Disease	2.8	2.1	0.33
Insomnia	0.5	0.4	0.25
Intelligence	0.4	0	0
Intracranial aneurysms	0.5		0.5
Irritable Bowel Syndrome	2.1	0.4	4.25
ischemic stroke	0.5	0.3	0.67
Liver Cirrhosis	2	1.3	0.54
Long COVID	1.4	0.9	0.56
Low bone mineral density		0.1	-0.1
Lung Cancer	0.4		0.4
Lymphoma	0.1		0.1
Mast Cell Issues / mastitis	0.9		0.9
ME/CFS with IBS	0.1	0.1	0
ME/CFS without IBS	0.6	0.1	5
membranous nephropathy	0.1		0.1
Menopause	0.1	0.1	0
Metabolic Syndrome	2.8	1.4	1
Mood Disorders	1.5	0.5	2
multiple chemical sensitivity [MCS]	0.4		0.4
Multiple Sclerosis	1.2	0.7	0.71
myasthenia gravis	0.3	0.1	2
neuropathic pain		0.2	-0.2
Neuropathy (all types)	0.1	0.3	-2
neuropsychiatric disorders (PANDAS, PANS)	0.4		0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic	1.3	0.2	5.5
NonCeliac Gluten Sensitivity	0.1	0.1	0
Obesity	1.9	2.3	-0.21
obsessive-compulsive disorder	1	0.7	0.43
Osteoarthritis	1.1	0.2	4.5
Osteoporosis	0.3	0.2	0.5
pancreatic cancer	0.7	0.1	6
Parkinson's Disease	1.6	2.2	-0.38
Polycystic ovary syndrome	1.6	0.7	1.29
Premenstrual dysphoric disorder		0	0
primary biliary cholangitis	0.1	0.6	-5
Primary sclerosing cholangitis	0.6	0.5	0.2
Psoriasis	0.7	0.3	1.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA)	1.9	0.8	1.37
Rosacea		0.1	-0.1
Schizophrenia	1	0.2	4
scoliosis	0.3	0.3	0
Sjögren syndrome	0.3	0.2	0.5
Sleep Apnea	0.4	0.2	1
Slow gastric motility / Gastroparesis	0.3		0.3
Small Intestinal Bacterial Overgrowth (SIBO)	0.8		0.8
Stress / posttraumatic stress disorder	0.9	0.2	3.5
Systemic Lupus Erythematosus	1.8	0.7	1.57
Tic Disorder	0.1	0	0
Tourette syndrome	0.1	0.1	0
Type 1 Diabetes	0.9	0.4	1.25
Type 2 Diabetes	2.2	1.3	0.69
Ulcerative colitis	1.7	0.9	0.89
Unhealthy Ageing	2.2	0.1	21
Vitiligo	0.5	0	0

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]